Document is current
Any future updates will be listed below
-
Authors
Zimmermann, Gregor S. https://orcid.org/0000-0003-0353-2523
Fingerle, Alexander A.
Renger, Bernhard
Laugwitz, Karl-Ludwig
Hautmann, Hubert
Sauter, Andreas
Meurer, Felix
Gassert, Florian Tilman
Bodden, Jannis
Müller-Leisse, Christina
Renz, Martin
Rummeny, Ernst J.
Makowski, Marcus R.
Willer, Konstantin
Noichl, Wolfgang
De Marco, Fabio
Frank, Manuela
Urban, Theresa
Schick, Rafael C.
Herzen, Julia
Koehler, Thomas
Haller, Bernhard
Pfeiffer, Daniela
Pfeiffer, Franz
-
Funding
Funding for this research was provided by:
philips medical systems dmc
h2020 european research council (AdG 695045)
Bundesministerium für Bildung und Forschung
Freistaat Bayern
Institute for Advanced Study, Technical University of Munich
Technische Universität München
- License Information
-
More Information
Article History
Received: 28 July 2021
Accepted: 4 January 2022
First Online: 1 March 2022
Declarations
:
: The research protocol was approved by the local Clinical Institutional Review Board and complies with the declaration of Helsinki. This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendment. The local ethics committee approved acquisition, processing, and publication of results from an anonymised data set. This study was approved by the Federal Office for Radiation Protection (Z5-22462/2-2017-021)*. Written consent was obtained from all patients and consent for publication was included. Written consent was obtained from all patients.
: Written consent was obtained from all patients and consent for publication was included.
: TK is employed at Royal Philips. With having technical background, the contribution was of methodic nature only. Apart from that, none of the funding sources were involved in the study design, data collection, data analysis, data interpretation, or writing of the report. GSZ received reports personal fees from AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, GSK, Novartis, and Roche. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. The other authors declare no competing interests.
